Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VLP Zika vaccine
- Development stage
- Preclinical
- Lead developer
- Saiba Biotech
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
VLP Zika vaccine is a preclinical-stage virus-like particle (VLP)-based vaccine being developed by Saiba Biotech for the prevention of Zika virus infection. The vaccine utilizes VLP technology to display Zika virus antigens on its surface, mimicking the structure of the virus without containing viral genetic material, which ensures it is non-infectious. It is designed to induce both neutralizing antibody and cellular immune responses to provide protection against the Zika virus. The development of this vaccine is a collaborative effort involving Saiba Biotech and several prominent academic institutions, including the University of Zurich, University of Oxford, ETH Zurich, University of Dundee, CHUV, The Jenner Institute, and A*STAR Singapore.
- Other names
- Zika virus-like particle vaccineSaiba Biotech Zika vaccine
02
Targets
ZIKV E (Zika virus envelope protein)
Beyond the preview
Go deeper on VLP Zika vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VLP Zika vaccine.